A case-control study to predict the risk of gestational diabetes mellitus by initial fasting blood sugar or past gestational history.

Int J Reprod Biomed

Department of Histology, Genetic of Non-communicable Diseases Research Center, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Published: April 2021

AI Article Synopsis

  • Gestational diabetes mellitus (GDM) is important to address due to potential health risks for both mothers and babies, highlighting the need for effective prevention and management.
  • A study involving 613 pregnant women in Tehran identified that 23.3% developed GDM, with significant risk factors including older maternal age, higher fasting blood sugar levels, and a history of complications in previous pregnancies.
  • The findings suggest that women with elevated initial fasting blood sugar and past gestational issues should be categorized as high risk and screened for GDM at an earlier stage of pregnancy.

Article Abstract

Background: Gestational diabetes mellitus (GDM) deserves proper prevention, diagnosis, and management due to healthcare implications from both maternal and fetal concerns.

Objective: To evaluate the rate and investigate the risk factors for developing GDM.

Materials And Methods: In this case-control, universal screening for GDM between 24 and 28 wk of gestation was performed in 613 pregnant women attending a prenatal clinic in Tehran who were followed-up until delivery between March 2017 to March 2018. Of the 613 women, 143 had GDM and 470 had normal glucose tolerance test as the primary diagnosis. Some GDM risk factors were compared in two groups.

Results: Impaired glucose tolerance test was detected in 143 (23.3%) patients. Prevalence of GDM was higher in the first-trimester fasting blood sugar (FBS) 90 qmg/dl group (p 0.001). Comparison of the GDM and the normal glucose tolerance test groups demonstrated significant differences in maternal age, first-trimester FBS, third-trimester vitamin D level, maternal platelet count, maternal body mass index (BMI) (before 12 wk of gestation), weight gain during pregnancy, and the history of gestational complications in previous pregnancy (p 0.01). In logistic regression, GDM was independently associated with older maternal age, higher first-trimester FBS, the history of gestational complications in previous pregnancy, lower third-trimester vitamin D level, and higher maternal platelet count (p 0.01).

Conclusion: Both patients with higher initial FBS and the history of gestational complications in previous pregnancy should be considered high risk for GDM and screened earlier.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106815PMC
http://dx.doi.org/10.18502/ijrm.v19i4.9064DOI Listing

Publication Analysis

Top Keywords

glucose tolerance
12
tolerance test
12
history gestational
12
gestational complications
12
complications previous
12
previous pregnancy
12
gestational diabetes
8
diabetes mellitus
8
fasting blood
8
blood sugar
8

Similar Publications

Cancer survivors have an increased risk of developing Type 2 diabetes compared to the general population. Patients treated with cisplatin, a common chemotherapeutic agent, are more likely to develop metabolic syndrome and Type 2 diabetes than age- and sex-matched controls. Surprisingly, the impact of cisplatin on pancreatic islets has not been reported.

View Article and Find Full Text PDF

Background: We aimed to evaluate how the parameters used in the diagnosis of metabolic syndrome (MetS) and parameters such as epicardial adipose tissue (EAT) thickness, insulin resistance (IR), and serum uric acid (SUA) are affected according to the severity of obesity.

Methods: A total of 120 obese patients aged 10-18 years were classified as class 1-2-3 according to their body mass index (BMI) score. SUA was measured and oral glucose tolerance tests were performed on all patients.

View Article and Find Full Text PDF

Effects of tryptophan-selective lipidated GLP-1 peptides on the GLP-1 receptor.

J Endocrinol

January 2025

N Inagaki, Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are widely used as antidiabetic and anti-obesity agents. Although conventional GLP-1 RAs such as liraglutide and semaglutide are acylated with fatty acids to delay their degradation by dipeptidylpeptidase-4 (DPP-4), the manufacturing process is challenging. We previously developed selectively lipidated GLP-1 peptides at their only tryptophan residue (peptide A having one 8-amino-3,6-dioxaoctanoic acid (miniPEG) linker and peptide B having three miniPEG linkers).

View Article and Find Full Text PDF

Purpose: Imeglimin is a novel oral antidiabetic agent that improves glucose tolerance. This study aimed to investigate the efficacy of combining imeglimin with dipeptidyl peptidase-4 inhibitor (DPP-4i), the most frequently prescribed first-line treatment for patients with type 2 diabetes (T2D) in Japan, to improve glycemic control.

Patients And Methods: Eleven patients with T2D treated with DPP-4i alone (6.

View Article and Find Full Text PDF

Long-term blood glucose control via glucose-activated transcriptional regulation of insulin analogue in type 1 diabetes mice.

Diabetes Obes Metab

January 2025

National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Aim: To achieve glucose-activated transcriptional regulation of insulin analogue in skeletal muscle of T1D mice, thereby controlling blood glucose levels and preventing or mitigating diabetes-related complications.

Materials And Methods: We developed the GANIT (Glucose-Activated NFAT-regulated INSA-F Transcription) system, an innovative platform building upon the previously established intramuscular plasmid DNA (pDNA) delivery and expression system. In the GANIT system, skeletal muscle cells are genetically engineered to endogenously produce the insulin analogue INSA-F (Insulin Aspart with Furin cleavage sites).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!